Unique ID issued by UMIN | UMIN000010294 |
---|---|
Receipt number | R000012050 |
Scientific Title | Efficacy and safety of early fibrinogen concentrate substitution therapy for severe trauma patients receiving massive transfusions: prospective single arm clinical trial |
Date of disclosure of the study information | 2013/04/01 |
Last modified on | 2018/09/10 23:09:04 |
Efficacy and safety of early fibrinogen concentrate substitution therapy for severe trauma patients receiving massive transfusions: prospective single arm clinical trial
Pilot study of early fibrinogen concentrate substitution therapy for severe trauma patients
Efficacy and safety of early fibrinogen concentrate substitution therapy for severe trauma patients receiving massive transfusions: prospective single arm clinical trial
Pilot study of early fibrinogen concentrate substitution therapy for severe trauma patients
Japan |
severe trauma
Surgery in general | Orthopedics | Neurosurgery |
Emergency medicine | Blood transfusion | Intensive care medicine |
Others
NO
To decide adequate dose of early fibrinogen concentrate substitution therapy for severe trauma patients receiving massive transfusions
Safety,Efficacy
Exploratory
Pragmatic
Phase II
the amount of blood transfusion for 24 hours after the hospital arriving
mortality for 72 hours after the hospital arriving
morbidity of venous thromboembolism during the hospital stay
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
freeze-dried human fibrinogen
Fibrinogen HT i.v. 1g - BENESIS
only the receiving injury day
dosage 2g or 3g/time
maximum of two times
Hemorrhagic trauma patients, whose serum fibrinogen concentration on admission is lower than 150mg/dl, are included in the trial. Freeze-dried human fibrinogen concentrate is administered once or twice within 24 hours of the injury. If the initial concentration is higher than 100mg/dl, 2g of the Fibrinogen is administered, else 3g is administered. Following the administration, the concentration is measured again. If the measurement is still lower than 150mg/dl, the second dose of Fibrinogen is administered according to the same criteria used to determine the initial dose. The concentration is measured again following the second administration.
12 | years-old | <= |
80 | years-old | > |
Male and Female
arrive at hospital within 3 hours after accident
shock or pre-shock
serum fibrinogen <=150mg/dl
(1)history of venous thromboembolism
(2)thrombotic diathesis (such as antithrombin deficiency,Protein S/C deficiency,antiphospholipid antibody syndrome)
(3)Agreement acquisition is impossible from the patient and the family.
30
1st name | |
Middle name | |
Last name | Koichi Inokuchi |
Saitama Medical Center, Saitama Medical University
Department of Emergency and Critical Care Medicine
Kawagoe-shi Kamoda 1981, JAPAN
0492283597
inok_k@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Koichi Inokuchi |
Saitama Medical Center, Saitama Medical University
Department of Emergency and Critical Care Medicine
Kawagoe-shi Kamoda 1981, JAPAN
0492283597
inok_k@saitama-med.ac.jp
Saitama Medical Center, Saitama Medical University
Saitama Medical Center, Saitama Medical University
Self funding
NO
埼玉医科大学総合医療センター (埼玉県)
2013 | Year | 04 | Month | 01 | Day |
Unpublished
Open public recruiting
2013 | Year | 03 | Month | 05 | Day |
2013 | Year | 05 | Month | 17 | Day |
2014 | Year | 03 | Month | 31 | Day |
2013 | Year | 03 | Month | 22 | Day |
2018 | Year | 09 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012050